Repligen Corp. (RGEN)
126.43
+0.67
(+0.53%)
USD |
NASDAQ |
May 07, 16:00
126.62
+0.19
(+0.15%)
Pre-Market: 20:00
Repligen Research and Development Expense (Annual) : 51.31M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Masimo Corp. | 126.40M |
| Orthofix Medical, Inc. | 65.85M |
| InfuSystem Holdings, Inc. | -- |
| Tandem Diabetes Care, Inc. | 174.84M |
| 908 Devices, Inc. | 13.80M |